A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
This research study is being done to measure the clinical benefit associated with cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs (organs other than bone or lymph nodes) and no longer responds to initial hormonal (castration) therapy. This type of prostate cancer is called metastatic, castrate-resistant prostate cancer.
Checked against the public recordLast updated Sep 27, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Edwin Posadas, MD
- Interventions being studied
- Drug: Cabozantinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
KEY INCLUSION CRITERIA \- mCRPC that includes visceral disease. Visceral metastatic disease is defined as solid organ infiltration that is not bone or lymph node metastases. KEY EXCLUSION CRITERIA * Recent history (\<6 months) of gastrointestinal hemorrhage requiring blood transfusion. * Tumor involvement in the intestinal lining which the treating physician deems at risk for perforation with rapid tumor response.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Cedars-Sinai Medical CenterLos Angeles, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 27, 2017. Always confirm current availability with the study team.